2024-519318-30-00
尚未招募
1 期
Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).
Wroclaw Medical University1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2025年3月27日最近更新:
概览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- Wroclaw Medical University
- 入组人数
- 18
- 试验地点
- 1
概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Information desk
Scientific
Wroclaw Medical University
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies2023-505204-34-00Schrodinger Inc.22
招募中
1/2 期
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)2023-505925-15-00Institut Gustave Roussy150
招募中
不适用
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid TumorsNCT07300150PAQ Therapeutics, Inc.195
招募中
不适用
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant TumorsNCT07266298Neowise Biotechnology24
尚未招募
1/2 期
Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)2025-521902-17-00Idp Discovery Pharma S.L.60